Advertisement
Singapore markets closed

  • Straits Times Index

    3,287.75
    -5.38 (-0.16%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • Dow

    38,460.92
    -42.77 (-0.11%)
     

  • Nasdaq

    15,712.75
    +16.11 (+0.10%)
     

  • Bitcoin USD

    62,978.15
    -3,109.36 (-4.70%)
     

  • CMC Crypto 200

    1,345.33
    -37.25 (-2.69%)
     

  • FTSE 100

    8,057.71
    +17.33 (+0.22%)
     

  • Gold

    2,332.60
    -5.80 (-0.25%)
     

  • Crude Oil

    82.24
    -0.57 (-0.69%)
     

  • 10-Yr Bond

    4.7190
    +0.0670 (+1.44%)
     

  • Nikkei

    37,628.48
    -831.60 (-2.16%)
     

  • Hang Seng

    17,284.54
    +83.27 (+0.48%)
     

  • FTSE Bursa Malaysia

    1,569.25
    -2.23 (-0.14%)
     

  • Jakarta Composite Index

    7,155.29
    -19.24 (-0.27%)
     

  • PSE Index

    6,574.88
    +2.13 (+0.03%)
     

Merck licenses experimental psoriasis drug to Sun Pharma

Reuters

(Reuters) - Merck & Co Inc (MRK.N) said it had licensed its experimental psoriasis drug to Indian generic maker Sun Pharmaceutical Industries Ltd (SUN.NS) for $80 million.

Under the agreement, Sun Pharma will acquire the worldwide rights to the drug, tildrakizumab, for all possible indications.

The drug is currently in late-stage trials for use in chronic plaque psoriasis, an inflammatory skin disease.

Merck will continue all clinical development and regulatory activities, which will be funded by Sun Pharma. Upon product approval, Sun Pharma will be responsible for regulatory activities, including manufacturing and marketing the approved product, the companies said.

ADVERTISEMENT

Merck's shares were down about 1 percent at $59.41 on the New York Stock Exchange on Wednesday. Sun Pharmaceutical's shares closed at 792.40 rupees on the National Stock Exchange of India.

(Reporting By Samantha Kareen Nair; Editing by Simon Jennings)